The science behind the most searched skin and hair concerns – and what the evidence actually recommends

Why Beauty Changes at This Life Stage – and Why It Matters

The perimenopause and menopause beauty market reached $600 billion in 2025 – not because women suddenly became vain, but because they finally started receiving answers to questions they had been asking for years. Skin that was manageable becomes dry and sensitive. Hair that was thick starts thinning. Acne that vanished in the 20s returns, inexplicably, in the late 40s. These are not cosmetic inconveniences. They are physiological changes driven by measurable hormonal shifts – and they deserve evidence-based attention.

This article addresses the three most searched and clinically relevant beauty concerns of perimenopause and menopause: collagen loss and skin barrier disruption, hormonal acne, and female pattern hair loss. For each, we explain the mechanism, the evidence, and what the science actually recommends.

TOPIC 1: COLLAGEN LOSS, SKIN BARRIER DISRUPTION, AND THE AGEING SKIN

The Mechanism: Why Skin Changes So Rapidly

Of all the visible changes in perimenopause and menopause, skin transformation is both the earliest and the most broadly experienced. Its speed and extent surprise many women – and the reason is primarily molecular.

Estrogen affects every tissue and organ of the human body, including the skin. Estrogen interacts with special kinds of cell receptors called estrogen receptors. These receptors are most abundant around the genital area, lower limbs, and the face – making these areas most vulnerable to reduced levels of circulating estrogen. 

The consequences of estrogen withdrawal on skin are multi-layered and simultaneous. The drop in estrogen levels during menopause catalyzes an accelerated process of bone and collagen resorption. According to the American Academy of Dermatology, collagen production drops 30% in the first five years of menopause and approximately 2% each year for about the next 20 years. Collagen gives skin plumpness and structure, and a slowed production leads to fine lines, wrinkles, and sagging skin. 

But collagen loss is only one dimension. Equally important is what happens to the skin barrier – the outermost protective layer that prevents water loss and shields against environmental irritants. Studies show that the skin barrier’s functionality is impacted by menopause: not only do ceramide levels decrease, so does the quality of those ceramides. Ceramides are the lipid molecules that hold skin cells together; without them, moisture escapes rapidly, skin becomes reactive, and irritation becomes chronic. 

Additionally, estrogen promotes the production of collagen, elastin, and hyaluronic acid, which helps maintain the skin’s plumpness, hydration, and elasticity. Conversely, low estrogen levels following menopause cause wrinkles and thinner, drier skin. 

What the Evidence Recommends

The clinical consensus from dermatologists is built around four evidence-based priorities:

Retinoids remain the gold standard. Topical retinoids stimulate fibroblast-mediated collagen synthesis, improve skin elasticity, and promote cell turnover – directly counteracting the molecular effects of estrogen loss. In perimenopause and early menopause, when skin is becoming more sensitive, a gradual introduction (two to three times weekly, with a rich moisturizer applied beforehand) minimizes irritation while preserving efficacy. Anti-ageing serums containing retinoids, retinol, vitamin C, peptides, and niacinamide are recommended to target wrinkles, fine lines, and age spots. 

Ceramide-rich moisturizers are non-negotiable. Given the quantified decline in ceramide levels at menopause, topical ceramide replenishment is the most direct intervention for barrier repair. Products combining ceramides with hyaluronic acid and glycerin address both the structural and hydration dimensions of menopausal skin simultaneously.

Sun protection is the single most impactful preventive step. UV exposure accelerates the collagen degradation that is already under hormonal pressure. A separate, dedicated sunscreen – not merely a moisturizer with SPF – applied in sufficient quantity and reapplied regularly, is essential for meaningful photoprotection. 

Products that previously worked may no longer be appropriate. Things that worked before menopause may not work anymore. Products once loved may be too drying, too sensitizing, or too weak for the skin’s new requirements. This is not a failure of the products – it is a signal that the skin’s needs have fundamentally changed. 

Aesthetic treatment considerations for the perimenopausal and menopausal patient represent a growing area of clinical interest, with dermatologists, gynecologists, and plastic surgeons increasingly collaborating on individualized treatment protocols. For women with significant collagen loss, in-clinic options – including microneedling, radiofrequency, and collagen-stimulating injectables – provide structural support that topical products alone cannot achieve. 

TOPIC 2: HORMONAL ACNE IN PERIMENOPAUSE AND MENOPAUSE

The Mechanism: Why Acne Returns After Decades

Adult acne in perimenopause is one of the most confusing and emotionally distressing beauty concerns of this life stage. Women who had clear skin throughout adulthood suddenly find themselves dealing with painful, persistent breakouts – often simultaneously with dry, thinning skin. The apparent paradox dissolves once the hormonal mechanism is understood.

Menopausal acne affects 12%–22% of women, causing significant emotional distress and quality of life impact, especially in those with darker skin due to scarring. Although perimenopausal and menopausal acne are becoming more common in dermatology clinics each year, it remains an underexplored area of research. 

As estrogen levels decline, there becomes an imbalance with levels of androgens such as testosterone, and this disruption to the hormonal balance can cause breakouts. Menopause breakouts are also explained by the change of sebum quality no longer controlled by estrogens. 

A 2024 review of adult acne and the influence of menopause identified hallmarks of menopause acne: it often impacts the area around the mouth and lower chin and may involve deep inflammatory nodules or cysts. This form of acne is often painful and persistent, and more prone to scarring. Whiteheads and enlarged pores may also appear around the cheeks and nose. 

This acne is categorically different from teenage acne. The skin in menopause is much drier, and acne doesn’t relate to the overproduction of sebum but mostly to impaired skin barrier, immune system reaction, and microbiome changes. The best results come from using gentle, microbiome-friendly skincare that suppresses inflammation and restores the skin microbiome’s health. 

What the Evidence Recommends

Treatment of menopausal acne requires a fundamentally different approach from acne at any other life stage. The central principle is anti-inflammatory management without further compromising the already-depleted skin barrier.

Treatment involves a stepwise approach, starting with gentle skincare and topical agents like salicylic acid, azelaic acid, and retinoids. Systemic therapies such as spironolactone and isotretinoin are reserved for severe or unresponsive cases, with spironolactone also addressing menopause-related symptoms. Hormone replacement therapy can improve skin integrity, reducing acne by maintaining dermal collagen and preventing barrier dysfunction. 

Spironolactone – an oral anti-androgen medication – has emerged as one of the most clinically relevant interventions for hormonally driven adult female acne. Spironolactone is an effective acne treatment with clinical trial data to support its use as a first-line treatment for women with acne, working by specifically targeting androgen-driven pathways and offering sustained improvement. 

Hormonal therapies are effective and well-tolerated options for acne, particularly in women with hormonal patterns or refractory disease. By specifically targeting androgen-driven pathways, hormonal agents offer sustained improvement and should be considered in the treatment algorithm. 

The gut-skin axis is also gaining clinical traction in this area. A 2025 clinical trial at a leading UK institution is investigating whether probiotic intervention can reduce perimenopausal inflammatory acne by modulating the immune response at the skin level – reflecting growing recognition that menopausal acne has systemic, not merely topical, dimensions.

For daily skincare: niacinamide (anti-inflammatory, barrier-supporting), azelaic acid (anti-bacterial and anti-inflammatory without over-drying), and low-dose retinoids are the cornerstone topical agents. Aggressive scrubbing, high-strength salicylic acid formulas, and oil-stripping cleansers should be avoided – they worsen the barrier dysfunction that is partly driving the breakouts.

TOPIC 3: FEMALE PATTERN HAIR LOSS IN PERIMENOPAUSE AND MENOPAUSE

The Mechanism: Why Hair Thins and What Drives It

Hair loss in perimenopause and menopause is among the most searched beauty concerns in this demographic – and one of the most emotionally significant. Alopecia, particularly frontal fibrosing alopecia (FFA) and female pattern hair loss (FPHL), showed the strongest postmenopausal associations, with most cases presenting after menopause and earlier or surgical menopause conferring greater risk. 

The biological mechanism is well understood. Androgenetic alopecia is the most common hair loss type in women. The pathophysiology involves shortened anagen phases, lengthened telogen phases, and hair follicle miniaturization. Androgens, particularly dihydrotestosterone (DHT), play a crucial role in its pathogenesis. 

Estrogen’s role in protecting hair is also direct: it prolongs the anagen (growing) phase of the hair cycle and suppresses the 5-alpha-reductase enzyme that converts testosterone to DHT. When estrogen falls, this protective mechanism weakens, the anagen phase shortens, and more follicles enter the resting phase simultaneously – producing the characteristic diffuse thinning women describe, along with widening of the parting line.

Progesterone also plays a role: its decline in early perimenopause – often preceding estrogen decline – further disinhibits 5-alpha-reductase activity, which is why many women notice hair changes beginning in their early to mid-40s, well before their last period.

Hair does naturally age – even without a genetic pattern of hair loss, each strand becomes finer and overall density can be less. But menopause-associated hair loss is distinct from natural ageing and responds to targeted intervention. 

What the Evidence Recommends

Topical minoxidil remains the only FDA-approved treatment for female pattern hair loss. In clinical studies that led to the FDA approval of minoxidil 2% solution, 19% of women reported moderate hair regrowth and 40% reported minimal regrowth after 8 months, compared to 7% of women using a placebo. In a 32-week, double-blind, placebo-controlled trial, 2% minoxidil led to new hair growth in 60% of women. Consistency and early treatment are key. 

Oral low-dose minoxidil has emerged as an important and increasingly prescribed option for women who struggle with the consistency or scalp effects of topical application. Studies from the Mayo Clinic and multiple international centers confirm its efficacy and tolerability at doses of 0.625–2.5 mg daily in women with FPHL.

Spironolactone (oral, anti-androgen) is increasingly used in combination with topical minoxidil for women with signs of androgen excess. A retrospective review demonstrated that the combination of oral minoxidil and spironolactone improved efficacy while maintaining safety in women with androgenetic alopecia. 

A major clinical development: in November 2025, Veradermics launched a Phase 2/3 trial for VDPHL01 – a proprietary extended-release oral minoxidil tablet that would, if approved, represent the first-ever prescription oral treatment specifically developed for women with pattern hair loss. The trial uses a gel-matrix delivery system designed to maintain sustained plasma concentrations while minimizing cardiovascular side effects – addressing one of the main limitations of existing oral minoxidil formulations.

Beyond pharmacology, nutritional support matters significantly. Adequate protein (for keratin synthesis), iron (frequently deficient in perimenopausal women due to heavy periods), zinc, and vitamin D are all co-factors in hair follicle function. Scalp massage – which increases blood flow to follicles – has demonstrated modest but real benefit in clinical studies and is accessible without prescription.

For women with significant hair loss, a trichologist or dermatologist with expertise in hair disorders can perform trichoscopy (digital scalp imaging) to distinguish between the types of hair loss and guide treatment selection. This assessment is worth seeking early, as earlier intervention consistently produces better outcomes.

The Overarching Message

Perimenopause represents a longer, more complex consumer and clinical journey than menopause itself – one characterized by fluctuating needs across skin, hair, sleep, mood, and intimacy. Perimenopause can begin in the early 30s and is universally experienced in the 40s, making it a distinct biological phase with its own set of needs, separate from menopause itself. 

The beauty changes of this transition are not vanity. They are barometers of hormonal health – visible, measurable signals of a systemic shift. Understanding the biology behind collagen loss, hormonal acne, and hair thinning transforms the response from anxiety to agency. With the right evidence-based approach – to both skincare and, where appropriate, systemic support – women can navigate this transition with their skin and hair health meaningfully protected.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE.

Sources

1. Tan J et al. Menopause and Common Dermatoses: A Systematic Review. American Journal of Clinical Dermatology. 2025.
2. Viscomi B et al. Managing Menopausal Skin: A Clinician’s Review. European Medical Journal – Dermatology. 2025. emjreviews.com
3. Bravo B et al. Dermatological Changes During Menopause and HRT: What to Expect? Cosmetics (MDPI). 2024;11(1):9. doi:10.3390/cosmetics11010009
4. Turner Dermatology / Woman’s World. MDs Share the Best Menopause Skin Care Routine + Products for Women Over 50. turnerdermatology.com. 2024.
5. Gallagher G. Understanding Menopause Skin Changes and What You Can Do. Healthline. Updated May 2025. healthline.com
6. Day D. The Menopause Skin Shift Is Real: What You Need to Know. NewBeauty. August 2025. newbeauty.com
7. BeautyMatter. The Perimenopause Opportunity Beauty Can’t Ignore. beautymatter.com. January 2026.
8. Round Table Discussion: Aesthetic Treatment Considerations for the Perimenopausal and Menopausal Patient. PMC12747467. 2025.
9. How to Best Support Women With Menopausal Acne. Dermatology Times. April 2025;46(4). dermatologytimes.com
10. Smith CA et al. Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists. Dermatology and Therapy. 2025;15(1):45–59. PMC11785877. doi:10.1007/s13555-024-01324-8
11. Tommasino N et al. Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review. Clinical, Cosmetic and Investigational Dermatology. 2025;18:3331–3337. doi:10.2147/CCID.S574341
12. Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial. ClinicalTrials.gov NCT07341087. 2025.
13. Burns LJ et al. Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review. Journal of the American Academy of Dermatology. 2025. doi:10.1016/S0190-9622(25)00722-4
14. Nohria A et al. Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy.PMC11470514. 2024.
15. Imhof R et al. Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss. PMC10483043. 2023.
16. Xia Y et al. Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis. Frontiers in Medicine. 2025. doi:10.3389/fmed.2025.1638496
17. Drugs.com / Hannemann K. Does minoxidil really work for women’s hair loss? Updated June 2025. drugs.com
18. Veradermics Launches Phase 2/3 Trial for VDPHL01. Dermatology Times. November 2025. dermatologytimes.